Scarica l'app Stockscreener
0.8164
3.18%
-0.0268
Precedente Chiudi:
$0.8432
Aprire:
$0.88
Volume 24 ore:
613.49K
Relative Volume:
1.15
Capitalizzazione di mercato:
$10.46M
Reddito:
-
Utile/perdita netta:
$-19.86M
Rapporto P/E:
-0.1209
EPS:
-6.7506
Flusso di cassa netto:
$-24.59M
1 W Prestazione:
-7.12%
1M Prestazione:
+13.39%
6M Prestazione:
-92.96%
1 anno Prestazione:
-95.21%
Intervallo 1D:
$0.7544
$0.88
Intervallo di 1 settimana:
$0.7544
$0.9104
Portata 52W:
$0.59
$23.20
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Nome
Reviva Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
(408) 501-8881
Indirizzo
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.8164 | 10.46M | 0 | -19.86M | -24.59M | -6.7506 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2023-09-20 | Iniziato | ROTH MKM | Buy |
| 2023-06-08 | Iniziato | The Benchmark Company | Speculative Buy |
| 2022-01-24 | Iniziato | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 50.79% to 38.15 - MSN
D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold - Investing.com
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN
Reviva Pharmaceuticals shares tumble after $9M public offering priced - MSN
Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52 - MSN
RVPH Should I Buy - Intellectia AI
Maxim Group downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
Reviva CEO to discuss brilaroxazine milestones in April 27 chat - Stock Titan
Reviva to Participate in a Fireside Chat Hosted by A.G.P. - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK) - The Globe and Mail
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans - Insider Monkey
What Analysts Say About Reviva (RVPH) Stock (Steady Decline) 2026-04-20Expert Stock Picks - Xã Thanh Hà
RVPH: Shareholder Letter Introduces New IP - Yahoo Finance
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces BankruptcyAmazon.com - Benzinga
Reviva Announces Letter to Shareholders - Sahm
Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 - Investing.com Australia
Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart
Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine By Investing.com - Investing.com Australia
Reviva Updates Brilaroxazine Strategy and Funding Outlook - TipRanks
Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine - Investing.com
Reviva Announces patent filing, FDA alignment plans and RECOVER-2 timing - TradingView
Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan
Aug Weekly: Is Reviva Pharmaceuticals Holdings Inc forming a bullish divergencePortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Growth Report: Can Reviva Pharmaceuticals Holdings Inc sustain earnings growthMarket Risk Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Minichart
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.885|Chg%:0.03 - TradingKey
Does Cobenfy Have the Potential to Become a Top Drug for BMY? - TradingView
Is institutional money flowing into Reviva (RVPH) Stock | Price at $0.79, Down 0.63%MA Crossover - Xã Thanh Hà
Short Squeeze: How do insiders feel about Reviva Pharmaceuticals Holdings Inc2026 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Investment Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart money2026 PreEarnings & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Energy Moves: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant impacted by rising rates2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Volume Summary: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant outperform during market rallies2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Aug Analyst Calls: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Form S-3Registration statement under Securities Act of 1933 - ADVFN
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Fundamental Analysis - Meyka
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Reviva Pharmaceuticals Holdings Inc Azioni (RVPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):